U.S. Healthcare Services Stock News

Texas Instruments stock snapshot and recent performance Texas Instruments (TXN) has been drawing investor attention after a strong run in recent months, with the stock last closing at $315.95 and showing solid gains over the past year. Over the past week, Texas Instruments is up 5.88%, with the move extending a month gain of 19.23% and a past 3 months gain of 48.96%. The stock’s 1 year total return stands at 75.58%, while the 3 year and 5 year total returns are 96.19% and 95.80%...

Wondering if Forgent Power Solutions at around US$47.56 is offering value or stretching expectations? This article walks through what the current price might be telling you. The stock has eased about 2% over the past week, but is still up 28.9% over the past month and 64.0% year to date, which can change how you think about both upside and risk. Recent coverage has focused on Forgent Power Solutions as investors look more closely at power and grid related companies, with attention on how its...

The Surface Transportation Board has paused and conditionally accepted the proposed merger between Union Pacific and Norfolk Southern. The decision brings heightened regulatory scrutiny and organized opposition from multiple state Attorneys General. The review process is expected to be intensive, with a focus on competition and potential business impacts across freight markets. Union Pacific, NYSE:UNP, is entering this review with its stock at $267.0 and a 15.1% return year to date. The...

Hecla Mining (HL) is back in focus after recent share price moves, with the stock up 3.8% on the day and modest gains over the past week, despite a weaker past 3 months. See our latest analysis for Hecla Mining. At a share price of US$17.59, Hecla’s near term momentum has softened, with the share price return down 29.39% over the past 90 days, even though the 1 year total shareholder return is very large. If you are looking beyond Hecla and want to see what else is moving in precious metals,...

Webull (BULL) has caught investor attention after recent trading, with the stock closing at US$6.33 and showing mixed performance across different periods, including a decline over the past month and a gain over the past 3 months. See our latest analysis for Webull. Looking beyond the latest move to US$6.33, Webull’s share price return is down 22.71% year to date and the 1 year total shareholder return is down 49.12%, indicating momentum has been weak despite an 8.95% 3 month share price...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Recent performance context for Federal Agricultural Mortgage (AGM) Federal Agricultural Mortgage (AGM) has drawn fresh attention after a period of mixed share performance, with modest gains in the past week and month, alongside a decline over the past year and stronger multi‑year total returns. See our latest analysis for Federal Agricultural Mortgage. With the share price at US$179.50 and a 90 day share price return of 13.85%, but a 1 year total shareholder return that is slightly down,...

Why National Beverage stock is drawing attention National Beverage (FIZZ) is back on investors’ radar after a recent share price move, with returns over the past month and past 3 months prompting closer scrutiny of its fundamentals and valuation. See our latest analysis for National Beverage. At a recent share price of US$37.24, the stock has a 1 month share price return of 7.91% and a year to date share price return of 17.62%, yet the 1 year total shareholder return is down 16.95%. This...

In late May, a Blue Origin New Glenn rocket exploded during testing, raising questions about future launch availability for AST SpaceMobile. The incident follows the loss of a BlueBird satellite in April due to a separate launch failure that affected the company’s deployment schedule. AST SpaceMobile has already shifted its next BlueBird batch to a planned mid June Falcon 9 launch with SpaceX from Cape Canaveral. The stock, NasdaqGS:ASTS, last closed at $133.09, with very large 1 year...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Garrett...

Wondering if Vulcan Materials at a recent US$276.75 close is priced appropriately for its future or offering limited value? This article walks through what the numbers actually say about the stock. Recent returns have been mixed, with the stock up 5.6% over the past week, down 5.0% over the past month, down 5.4% year to date, and up 5.1% over the past year, which can signal changing views on both opportunity and risk. Recent news flow around Vulcan Materials has centered on ongoing interest...

Recent performance and scale Berkshire Hathaway (BRK.B) has drawn investor attention after recent trading, with the stock down around 5% over the past 3 months and about 4% year to date, closing at US$477.42. See our latest analysis for Berkshire Hathaway. For context, Berkshire Hathaway’s recent share price weakness has been relatively steady rather than abrupt, with a 90 day share price return of about a 5% decline, while the 3 year total shareholder return of around 48% reflects a stronger...

The United States market has shown robust performance recently, climbing 1.8% in the last seven days and rising 28% over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying small-cap stocks that are potentially undervalued and experiencing insider action can present unique opportunities for investors seeking to capitalize on growth prospects within emerging companies.

EyePoint Pharmaceuticals recently presented at the Stifel 2026 Virtual Ophthalmology Forum and reiterated that top-line Phase 3 data for its wet age-related macular degeneration (AMD) therapy DURAVYU are expected to begin reading out in August, with a second pivotal trial to follow about two months later. Management highlighted 2026 as potentially transformative, emphasizing ambitions for DURAVYU to match a leading therapy on vision outcomes while maintaining safety and reducing treatment...

Lantheus Holdings (NasdaqGM:LNTH) plans to present new clinical data for LNTH-2403, an LRRC15-targeted radiopharmaceutical, at the 2026 ASCO Annual Meeting. The company will also share real-world data on piflufolastat F 18 imaging use in early-stage prostate cancer at the same conference. These updates provide fresh detail on both Lantheus's osteosarcoma pipeline and the adoption of its approved prostate cancer imaging agent. Lantheus focuses on radiopharmaceuticals and imaging agents used...

Over the last 7 days, the United States market has risen 1.8% and in the past year, it has climbed 28%, with earnings expected to grow by 17% per annum over the next few years. In this environment, identifying high growth tech stocks involves looking at companies that not only show strong potential for revenue expansion but also align well with these positive market trends.

Capital One Financial (NYSE:COF) is moving Discover’s credit card portfolio onto Capital One’s own back-office platform as part of the merger process. The integration focuses on consolidating technology systems and operational processes used to service and process Discover credit card accounts. The back-office migration is expected to influence cost efficiency, revenue opportunities, and how the combined company competes in card processing. For you as an investor, this move sits at the...

The United States market has shown robust performance, rising 1.8% over the last week and climbing 28% in the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying stocks that are trading below their estimated value can offer potential opportunities for investors looking to capitalize on market growth while minimizing risk.

COMPASS Pathways (NasdaqGS:CMPS) has appointed Kathleen Tregoning to its Board of Directors. Tregoning brings extensive biotech and pharmaceutical leadership experience, including roles at Cerevel Therapeutics and other large drugmakers. The appointment is intended to support COMPASS Pathways as it advances late stage programs and prepares for potential commercialization. For investors tracking mental health treatment companies, COMPASS Pathways focuses on developing therapies for...

Citizens Financial Group stock overview Citizens Financial Group (CFG) drew fresh investor interest after recent share performance data highlighted mixed short term moves, including a decline over the past month alongside gains over the past three months and the past year. See our latest analysis for Citizens Financial Group. At a latest share price of $62.41, Citizens Financial Group has seen short term share price pressure, with declines over the past month. Longer term total shareholder...

Indivior Pharmaceuticals (INDV) is back in focus after a recent period of strong longer term returns, with the stock up about 195% over the past year and about 102% over the past 3 months. See our latest analysis for Indivior Pharmaceuticals. Recent trading has cooled slightly, with the share price down about 1% over the past day and about 2% over the week. However, the 30 day share price return of 6% sits alongside a very strong 1 year total shareholder return of 195%. This suggests momentum...

Syncfusion’s BoldSign e-signature integration is now available in the HubSpot Marketplace. The launch brings enterprise-grade e-signature workflows directly into HubSpot’s CRM. BoldSign joins the HubSpot Technology Partner Program, adding new compliance-focused document tools for customer-facing teams. For investors tracking NYSE:HUBS, this move adds another workflow tool inside HubSpot’s core CRM environment, an area where many software providers are competing to become a central operating...

Anyone interested in Rigetti Computing, Inc. ( NASDAQ:RGTI ) should probably be aware that the Chief Technology...

If you are wondering whether CECO Environmental at US$83.31 is priced for more growth or already baking in high expectations, the starting point is to understand what the current valuation actually reflects. The stock has seen very strong recent returns, with 3.3% over the past week, 12.1% over the last month, 39.3% year to date and a very large 1 year gain of 204.7%, alongside an even larger 3 year return and close to a 10x move over 5 years. Recent coverage has focused on CECO...